The MPZL3 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from Raji B lymphocytes, providing a loss-of-function model for MPZL3. This product enables targeted gene disruption without single-cell cloning, offering a genetically diverse yet functionally homogeneous system for investigating MPZL3-dependent mechanisms in a lymphoid cell context.
Raji is an immortalized B lymphocyte line from an EBV-positive Burkitt lymphoma. These lymphoblastoid cells are extensively characterized for lymphoma and EBV research, exhibiting rapid growth and active signaling pathways. The Raji background provides a disease-relevant model to study MPZL3 in malignant B cells, particularly roles in integrin-mediated adhesion and migration that influence lymphoma biology and tumor cell dissemination.
MPZL3 is a fibronectin-binding receptor that recruits SHP-2 phosphatase (PTPN11) to the plasma membrane, negatively regulating integrin signaling. Upon fibronectin engagement, MPZL3 activates SHP-2, which dephosphorylates FAK/PTK2 and SRC, attenuating PI3K-AKT and MAPK/ERK cascades. Upstream regulators include extracellular matrix, BCR stimulation, and CXCL12. Downstream targets include AKT1, MAPK1/3, and integrins ITGB1/ITGB7. Ezrin (EZR) links the complex to the actin cytoskeleton. MPZL3 knockout ablates SHP-2-mediated feedback, causing hyperphosphorylation of FAK and AKT, with altered adhesion and migration.
In Raji B cells, MPZL3 knockout disrupts the regulatory circuits controlling adhesion and homing. This perturbation mimics pathophysiological conditions where integrin signaling is dysregulated, such as lymphoma metastasis. The model allows dissection of MPZL3’s role in modulating B lymphocyte interaction with the microenvironment, enabling studies on how loss of this receptor affects tumor cell motility and integrin surface expression. It serves as a valuable tool for investigating the molecular basis of adhesion-related disorders and for evaluating MPZL3 as a therapeutic target.
Applications include cell adhesion and Transwell migration assays, flow cytometry for integrin expression, Western blotting for phospho-FAK and phospho-AKT, immunofluorescence of focal adhesion components, and co-immunoprecipitation of SHP-2. These cells are also suitable for high-throughput screening. For technical support or sample requests, contact Ascent Research.
